Is it safe?
Can CRL take a bad year?
Charles River Laboratories carries $2.43B of net debt at 6.27× EBITDA: a heavy load to carry through a bad year.
$2.43B
Net debt · as at Q2 2026 · over four years of earnings before interest, tax and depreciation, heavy
- Net debt / EBITDA
- 6.27×
Net debt / EBITDA · 3.88× a year ago · the load is going up
- Altman Z-score
- 2.40
Altman Z-score · grey zone, between 1.8 and 3
- Interest cover
- 0.85×
Interest cover · operating profit barely covers the interest bill
Details›
- Total debtQ2 2026
- $2.63B
- Cash and short-term investments
- $192M
- Net debt
- $2.43B
- EBITDA, trailing twelve months
- $388M
- Operating profit, trailing twelve months
- $90M
- Debt / equity
- 0.93×
- Total debt / EBITDA
- 6.77×
- Annualised volatilitytwo years of daily moves
- 52%
- Worst drawdown on file
- −78%
- Below its 52-week high
- −1.2%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Diagnostics & Research
Ranks #17 of 29 by Smart Score